AbbVie Inc. is 30.8x more valuable than Axsome Therapeutics, Inc. by market capitalization ($397.44 B vs $12.91 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AXSM | ABBV |
|---|---|---|
| Market cap | $12.91 B | $397.44 B |
| US-listed rank | #801 | #28 |
| Revenue (latest FY) | $638.50M | $61.16B |
| Net income (latest FY) | -$183.17M | $4.23B |
| Net margin | -28.7% | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 634 | 1,008 |
AbbVie Inc. is 30.8x more valuable than Axsome Therapeutics, Inc. by market capitalization ($397.44 B vs $12.91 B).
In their latest fiscal years, Axsome Therapeutics, Inc. reported $638.50M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Axsome Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.